+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic Ovarian Syndrome Treatment Market by Drug Class, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021814
  • Report
  • January 2020
  • Region: Global
  • 217 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Allergan plc.
  • AstraZeneca plc.
  • Bayer AG
  • Johnson Johnson
  • Mylan N.V.
  • Novartis AG
The global polycystic ovarian syndrome treatment market was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026. Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.



The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and an increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class
  • Insulin Sensitizing Agent
  • Oral Contraceptive
  • Antiandrogens
  • Anti-Obesity Drugs
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Allergan plc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Johnson and Johnson
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • SANOFI
  • Teva Pharmaceutical Industries

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Merck KGaA
  • Ferring BV
Frequently Asked Questions about the Global Polycystic Ovarian Syndrome Treatment Market

What is the estimated value of the Global Polycystic Ovarian Syndrome Treatment Market?

The Global Polycystic Ovarian Syndrome Treatment Market was estimated to be valued at $2902.0 million in 2018.

What is the growth rate of the Global Polycystic Ovarian Syndrome Treatment Market?

The growth rate of the Global Polycystic Ovarian Syndrome Treatment Market is 4.7%, with an estimated value of $4184.0 million by 2026.

What is the forecasted size of the Global Polycystic Ovarian Syndrome Treatment Market?

The Global Polycystic Ovarian Syndrome Treatment Market is estimated to be worth $4184.0 million by 2026.

Who are the key companies in the Global Polycystic Ovarian Syndrome Treatment Market?

Key companies in the Global Polycystic Ovarian Syndrome Treatment Market include Allergan plc., AstraZeneca plc., Bayer AG, Bristol, Myers Squibb Company, Johnson Johnson, Mylan N.V., Novartis AG and SANOFI.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan plc.
  • AstraZeneca plc.
  • Bayer AG
  • Johnson Johnson
  • Mylan N.V.
  • Novartis AG

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Key Findings
2.2.1. Top Investment Pockets
2.2.2. Market Player Positioning, 2018
2.3. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Forces Shaping Polycystic Ovarian Syndrome Treatment Industry/Market
3.2.1. Moderate Power of Suppliers
3.2.2. High Threat of New Entrants
3.2.3. High Threat of Substitution
3.2.4. Moderate Competitive Rivalry
3.2.5. Moderate Bargaining Power of Buyers
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Increase In Prevalence of Pcos
3.3.1.2. Increase In Number of Pipeline Drugs
3.3.1.3. Surge In Healthcare Expenditure Worldwide
3.3.2. Restraint
3.3.2.1. Lack of Approved Therapeutics For Treatment of Pcos
3.3.3. Opportunities
3.3.3.1. Growth Opportunities In Emerging Markets
3.3.3.2. Higher Number of Unmet Needs For Treatment of Pcos
3.3.4. Impact Analysis
Chapter 4: Polycystic Ovarian Syndrome Treatment Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Insulin Sensitizing Agent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Oral Contraceptive
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Antiandrogens
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Anti-Obesity Drugs
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Others
4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis, By Country
Chapter 5: Polycystic Ovarian Syndrome Treatment Market, By End User
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Hospitals Pharmacies
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Drug Stores And Retail Pharmacies
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Online Pharmacies
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country
Chapter 6: Polycystic Ovarian Syndrome Treatment Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends, Growth Factors, And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.2.1. U.S.
6.2.2.1.1. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.1.2. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.2.2. Canada
6.2.2.2.1. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.2.2. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.2.2.3.2. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3. Europe
6.3.1. Key Market Trends, Growth Factors, And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.2.1. Germany
6.3.2.1.1. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.1.2. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.2. France
6.3.2.2.1. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.2.2. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.3. UK
6.3.2.3.1. UK Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.3.2. UK Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.4. Italy
6.3.2.4.1. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.4.2. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.5. Spain
6.3.2.5.1. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.5.2. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.3.2.6.2. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3.3. Europe Market Size And Forecast, By Drug Class
6.3.4. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4. Asia-Pacific
6.4.1. Key Market Trends, Growth Factors, And Opportunities
6.4.2. Market Size And Forecast, By Country
6.4.2.1. Japan
6.4.2.1.1. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.1.2. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.2. China
6.4.2.2.1. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.2.2. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.3. Australia
6.4.2.3.1. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.3.2. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.4. India
6.4.2.4.1. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.4.2. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.5.2. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.4.2.6.2. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5. LAMEA
6.5.1. Key Market Trends, Growth Factors, And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.1.2. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.2.2. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.3.2. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Polycystic Ovarian Syndrome Treatment Market, By Drug Class
6.5.2.4.2. Rest of LAMEA Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5.3. LAMEA Market Size And Forecast, By Drug Class
6.5.4. LAMEA Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
Chapter 7: Company Profiles
7.1. Allergan Plc
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Astrazeneca Plc
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bayer Ag.
7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Product Portfolio
7.3.4. Business Performance
7.4. Bristol-Myers Squibb Company
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Johnson And Johnson
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Mylan N.V
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Novartis Ag
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Pfizer Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Sanofi
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.10. Teva Pharmaceutical Industries
7.10.1. Company Overview
7.10.2. Operating Business Segments
7.10.3. Product Portfolio
7.10.4. Business Performance
7.10.5. Key Strategic Moves And Developments
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan plc.
  • AstraZeneca plc.
  • Bayer AG
  • Johnson Johnson
  • Mylan N.V.
  • Novartis AG
According to the report, titled, 'Polycystic Ovarian Syndrome Treatment Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, growing at a CAGR of 4.7% from 2019 to 2026.

Polycystic ovarian syndrome or PCOS is a hormonal disorder that occurs in women during their childbearing age and is characterized by formation of cyst on ovaries. PCOS often leads to hirsutism, obesity, infertility, and diabetes, thus, needs effective management. Presently, there is no cure for PCOS, but different types of medications, such as insulin sensitizing agent, oral contraceptive, antiandrogens, and anti-obesity drugs are used to manage PCOS.

The polycystic ovarian syndrome treatment market is expected to experience significant growth during the forecast period owing to rise in demand for PCOS treatment medication across different regions and an increase in popularity combination therapy majorly drives the market growth. Increase in prevalence of PCOS is expected to further boost the polycystic ovarian syndrome treatment market growth during the forecast period. In addition, significant unmet need for PCOS treatment, increase in R&D activities to develop PCOS therapeutics, and growing demand forof PCOS therapeutics in developing countries further creates opportunities for the PCOS treatment market. However, lack of approved drugs and adverse effects associated with off label drugs are anticipated to hamper the market growth.

On the basis of drug class, the market is categorized into insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. Presently, the insulin sensitizing agent segment is the major revenue contributing segment and is estimated to show a significant market growth during the forecast period, owing to higher adoption of insulin sensitizing agents as first line treatment in the management of PCOS.

According to distribution channel, the polycystic ovarian syndrome treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, attributed to the rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.

Key Findings of the Study
Based on drug class, the insulin sensitizing agent segment held more than one half of share in the global market in 2018.
Based on end user, the online providers segment exhibits fastest growth and is expected to grow at a CAGR of 6.3% from 2019 to 2026.
Based on end user, the drug stores & retail pharmacies segment held the largest market share in 2018 and is expected to remain dominant throughout the forecast period.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period.
North America accounted for approximately one-half of the global polycystic ovarian syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to the rise in adoption of polycystic ovarian syndrome treatment medications, well developed healthcare infrastructure, large number of target population with higher health awareness, wide availability of advanced polycystic ovarian syndrome treatment therapeutics, and supportive reimbursement policies in the healthcare system. In addition, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of PCOS, and an increase in the adoption of polycystic ovarian syndrome treatment medication for the same.
Note: Product cover images may vary from those shown
  • Allergan plc.
  • AstraZeneca plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Johnson Johnson
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • SANOFI
  • Teva Pharmaceutical Industries.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...